Landscape of BCL2 Resistance Mutations in a Real-World Cohort of Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia Treated with Venetoclax.

doi:10.3390/ijms24065802

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Community

Back to search

Article

Landscape of BCL2 Resistance Mutations in a Real-World Cohort of Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia Treated with Venetoclax.

International journal of molecular sciences - 18 Mar 2023

Kotmayer Lili, László Tamás, Mikala Gábor, Kiss Richárd, Lévay Luca, Hegyi Lajos László, Gróf Stefánia, Nagy Tibor, Barna Gábor, Farkas Péter, Weisinger Júlia, Nagy Zsolt, Balogh Alexandra, Masszi Tamás, Demeter Judit, Sulák Adrienn, Kohl Zoltán, Alizadeh Hussain, Egyed Miklós, Pettendi Piroska, Gergely Lajos, Plander Márk, Pauker Zsolt, Masszi András, Matolcsy András, Szász Róbert, Bödör Csaba, Alpár Donát

Abstract excerpt

The oral, highly selective Bcl2 inhibitor venetoclax has substantially improved the therapeutic landscape of chronic lymphocytic leukemia (CLL). Despite the remarkable response rates in patients with relapsed/refractory (R/R) disease, acquired resistance is the leading cause of treatment failure, with somatic BCL2 mutations being the predominant genetic drivers underpinning venetoclax resistance. To assess the...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antineoplastic Agents

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Antineoplastic Combined Chemotherapy Protocols

Share to Bridged Bicyclo Compounds, Heterocyclic

Share to Disease Progression

Share to Drug Resistance, Neoplasm

Share to Leukemia, Lymphocytic, Chronic, B-Cell

Share to Proto-Oncogene Proteins c-bcl-2

Share to Recurrence

Source

Open in PubMed Open full text

Identifiers

PMID: 36982875
DOI: 10.3390/ijms24065802
PMCID: PMC10058128

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Landscape of BCL2 Resistance Mutations in a Real-World Cohort of Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia Treated with Venetoclax.PMID 36982875Read ↗

Acquisition of the Recurrent Gly101Val Mutation in BCL2 Confers Resistance to Venetoclax in Patients with Progressive Chronic Lymphocytic LeukemiaSemantic proximity Read ↗

Clonal dynamics towards the development of venetoclax resistance in chronic lymphocytic leukemia.Semantic proximity Read ↗

Genetic events associated with venetoclax resistance in CLL identified by whole-exome sequencing of patient samplesSemantic proximity Read ↗

Resistance-Associated Mutations in Chronic Lymphocytic Leukemia Patients Treated With Novel AgentsSemantic proximity Read ↗

Understanding and Targeting BCL2-inhibitor Resistance in Chronic Lymphocytic Leukemia.Semantic proximity Read ↗

Efficacy of venetoclax in high risk relapsed mantle cell lymphoma (MCL) - outcomes and mutation profile from venetoclax resistant MCL patients.Semantic proximity Read ↗

Multiple BCL2 mutations cooccurring with Gly101Val emerge in chronic lymphocytic leukemia progression on venetoclaxSemantic proximity Read ↗

Single-cell sequencing demonstrates complex resistance landscape in CLL and MCL treated with BTK and BCL2 inhibitors.Semantic proximity Read ↗

Novel BCL2 mutations in venetoclax-resistant, ibrutinib-resistant CLL patients with BTK/PLCG2 mutationsSemantic proximity Read ↗

Single-cell multiomics reveal the scale of multilayered adaptations enabling CLL relapse during venetoclax therapySemantic proximity Read ↗

Sonrotoclax overcomes BCL2 G101V mutation-induced venetoclax resistance in preclinical models of hematologic malignancy.Semantic proximity Read ↗

Characterization of a novel venetoclax resistance mutation (BCL2 Phe104Ile) observed in follicular lymphomaSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.